Your Health, We Care
Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
from FDA，2024.01
Koselugo is a class of precision small molecule MEK inhibitors (also regarded as···【more】
Release date：2024-08-22Recommended：132
Koselugo is a small molecule MEK inhibitor (figogen activation inhibitor) that i···【more】
Release date：2024-08-22Recommended：144
Koselugois a small molecule drug inhibitor targeting the MEK signaling pathway, ···【more】
Release date：2024-08-21Recommended：123
